Greenlight Biosciences Holdings PBCNASDAQ:GRNA
- LAST PRICE0.9589
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0000/ 3
- Ask / Lots1.0500/ 16
- Open / Previous Close1.0500 / 0.9589
- Day Range
- 52 Week Range
- Volume202,730
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRNA |
|---|---|---|
| 09:32 ET | 709 | 1.05 |
| 09:35 ET | 459 | 1.05 |
| 09:46 ET | 1201 | 1.0753 |
| 09:50 ET | 200 | 1.07 |
| 09:57 ET | 300 | 1.05 |
| 10:08 ET | 100 | 1.08 |
| 10:13 ET | 1300 | 1.07 |
| 10:15 ET | 500 | 1.06 |
| 10:18 ET | 200 | 1.07 |
| 10:20 ET | 100 | 1.06 |
| 10:22 ET | 100 | 1.06 |
| 10:26 ET | 200 | 1.065 |
| 10:33 ET | 4093 | 1.055 |
| 10:36 ET | 3762 | 1.055 |
| 10:40 ET | 555 | 1.05 |
| 10:44 ET | 300 | 1.06 |
| 10:45 ET | 300 | 1.06 |
| 10:47 ET | 400 | 1.06 |
| 10:54 ET | 100 | 1.055 |
| 10:56 ET | 100 | 1.055 |
| 10:58 ET | 100 | 1.055 |
| 11:00 ET | 283 | 1.05 |
| 11:02 ET | 300 | 1.05 |
| 11:07 ET | 3205 | 1.03 |
| 11:09 ET | 2605 | 1.03 |
| 11:12 ET | 4684 | 1.01 |
| 11:14 ET | 8060 | 1 |
| 11:18 ET | 477 | 1.005 |
| 11:20 ET | 200 | 1.005 |
| 11:21 ET | 1300 | 1.005 |
| 11:23 ET | 100 | 1.005 |
| 11:25 ET | 1414 | 1.01 |
| 11:27 ET | 1100 | 1.01 |
| 11:30 ET | 2902 | 1.01 |
| 11:38 ET | 200 | 1.02 |
| 11:39 ET | 100 | 1.02 |
| 11:41 ET | 100 | 1.02 |
| 11:43 ET | 543 | 1.02 |
| 11:45 ET | 200 | 1.015 |
| 11:48 ET | 1600 | 1.015 |
| 11:50 ET | 100 | 1.015 |
| 11:59 ET | 500 | 1.015 |
| 12:01 ET | 100 | 1.01 |
| 12:03 ET | 200 | 1.01 |
| 12:06 ET | 1600 | 1.01 |
| 12:08 ET | 200 | 1.015 |
| 12:10 ET | 100 | 1.015 |
| 12:12 ET | 400 | 1.01 |
| 12:15 ET | 100 | 1.01 |
| 12:17 ET | 300 | 1.015 |
| 12:21 ET | 400 | 1.015 |
| 12:24 ET | 100 | 1.015 |
| 12:26 ET | 100 | 1.015 |
| 12:28 ET | 300 | 1.01 |
| 12:30 ET | 187 | 1.01 |
| 12:32 ET | 300 | 1.01 |
| 12:33 ET | 200 | 1.015 |
| 12:35 ET | 2000 | 1.0199 |
| 12:37 ET | 253 | 1.01 |
| 12:39 ET | 300 | 1.015 |
| 12:42 ET | 6968 | 1.019 |
| 12:44 ET | 800 | 1.0189 |
| 12:46 ET | 1047 | 1.01 |
| 12:48 ET | 100 | 1.015 |
| 12:50 ET | 1700 | 1.015 |
| 12:51 ET | 100 | 1.015 |
| 12:53 ET | 100 | 1.015 |
| 12:55 ET | 100 | 1.015 |
| 01:00 ET | 300 | 1.01 |
| 01:02 ET | 200 | 1.01 |
| 01:04 ET | 350 | 1.015 |
| 01:06 ET | 100 | 1.015 |
| 01:08 ET | 700 | 1.015 |
| 01:09 ET | 100 | 1.015 |
| 01:15 ET | 700 | 1.015 |
| 01:18 ET | 300 | 1.0186 |
| 01:20 ET | 200 | 1.015 |
| 01:27 ET | 10990 | 1.02 |
| 01:31 ET | 341 | 1.03 |
| 01:33 ET | 200 | 1.03 |
| 01:36 ET | 200 | 1.02 |
| 01:42 ET | 100 | 1.02 |
| 01:44 ET | 100 | 1.025 |
| 01:45 ET | 200 | 1.025 |
| 01:47 ET | 300 | 1.02 |
| 01:56 ET | 236 | 1.02 |
| 02:00 ET | 516 | 1.02 |
| 02:05 ET | 100 | 1.025 |
| 02:07 ET | 200 | 1.02 |
| 02:14 ET | 104 | 1.02 |
| 02:16 ET | 100 | 1.025 |
| 02:18 ET | 892 | 1.02 |
| 02:23 ET | 200 | 1.02 |
| 02:30 ET | 200 | 1.02 |
| 02:32 ET | 200 | 1.02 |
| 02:34 ET | 100 | 1.02 |
| 02:36 ET | 700 | 1.025 |
| 02:38 ET | 200 | 1.02 |
| 02:39 ET | 100 | 1.025 |
| 02:41 ET | 400 | 1.02 |
| 02:48 ET | 100 | 1.025 |
| 02:50 ET | 2908 | 1.02 |
| 02:52 ET | 100 | 1.025 |
| 02:54 ET | 100 | 1.025 |
| 02:56 ET | 1100 | 1.02 |
| 02:57 ET | 100 | 1.025 |
| 02:59 ET | 100 | 1.025 |
| 03:01 ET | 100 | 1.025 |
| 03:03 ET | 379 | 1.02 |
| 03:08 ET | 100 | 1.025 |
| 03:10 ET | 100 | 1.025 |
| 03:12 ET | 400 | 1.025 |
| 03:14 ET | 100 | 1.025 |
| 03:21 ET | 524 | 1.02 |
| 03:26 ET | 200 | 1.02 |
| 03:32 ET | 4421 | 1.015 |
| 03:37 ET | 300 | 1.01 |
| 03:42 ET | 700 | 1.01 |
| 03:44 ET | 200 | 1.015 |
| 03:51 ET | 1560 | 1.01 |
| 03:53 ET | 100 | 1.01 |
| 03:55 ET | 2298 | 1.01 |
| 03:57 ET | 37661 | 0.983 |
| 04:00 ET | 11245 | 0.9589 |
Feb 1, 2023
GreenLight Biosciences Secures Rwanda FDA Approval for COVID-19 Clinical Trial, from 10:50AM ET on Wednesday Feb 01, 2023 by MT Newswires
10:50AM ET on Wednesday Feb 01, 2023 by MT NewswiresBRIEF-Greenlight Biosciences Receives Approval To Initiate Phase I/II Clinical Trial Of Covid-19 mRNA Vaccine Candidate, from 7:23AM ET on Wednesday Feb 01, 2023 by Thomson Reuters
7:23AM ET on Wednesday Feb 01, 2023 by Thomson ReutersGreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate, from 7:21AM ET on Wednesday Feb 01, 2023 by GlobeNewswire
7:21AM ET on Wednesday Feb 01, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Greenlight Biosciences Holdings PBC | 159.1M | -0.7x | --- |
Chimerix Inc | 160.2M | 1.0x | --- |
VBI Vaccines Inc | 159.6M | -1.4x | --- |
Trevi Therapeutics Inc | 158.8M | -3.0x | --- |
Nuvectis Pharma Inc | 159.5M | 0.0x | --- |
Merrimack Pharmaceuticals Inc | 159.9M | -104.6x | --- |
Company Information
GreenLight Biosciences Holdings, PBC is a biotechnology company. The Company is focused on Ribonucleic acid (RNA) research, design, and manufacturing for human, animal, and plant health. The Company has developed technology to create high-performing, natural ribonucleic acid (RNA) products to address global sustainability challenges and promote healthier plants, foods, and people. The Company is engaged in the cell-free biomanufacturing platform. This platform enables the making of complex biological molecules nucleic acids, peptides, carbohydrates, and many others which allows manufacturing products at a lower cost than traditional methods using fermentation. The platform is used to develop and commercialize products. The Company's pipeline for plant and animal health includes Colorado potato beetle, Botrytis cinerea, Varroa mites, Fungicides, Grapevine powdery mildew, Fusarium Head Blight (FHB), Lepidoptera, and Powdery mildew.
Contact Information
- Headquarters
- 200 Boston Avenue, Suite 3100MEDFORD, MA, United States 02155
- Phone
- 617-616-8188
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Charles Cooney
- President, Chief Executive Officer, Co-Founder, Director
- Andrey Zarur
- Chief Financial Officer, Interim Chief Accounting Officer
- Susan Keefe
- Chief Operating Officer
- Carole Cobb
- Chief People Officer
- Charu Manocha
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $159.1M |
|---|---|
Revenue (TTM) | $4.2M |
Shares Outstanding | 151.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.31 |
Book Value | $-0.24 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 38.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,803.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
